Editor’s note: Shortly after this column was published, Mylan pharmaceuticals announced it will begin distributing Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda’s Ampyra. There’s been no word, yet, on what it will cost or how soon the generic will become available in pharmacies.
A few years ago, I had to give up using Ampyra (dalfampridine), the MS medication that can improve walking speed. Though I felt that the medication did slightly improve my speed, a change in insurance made its out-of-pocket costs excessive for me.
But now, thanks to a court ruling, we may be closer to the day when a generic version of Ampyra is available. Presumably, that generic would be more affordable. A few days ago a U.S. Court of Appeals upheld a lower court ruling that had invalidated four key patents held by Ampyra’s manufacturer, ... read more at: https://multiplesclerosisnewstoday.com/2018/09/18/ms-generic-ampyra-gets-closer/